Cargando…

Implications of advanced oxidation protein products (AOPPs), advanced glycation end products (AGEs) and other biomarkers in the development of cardiovascular diseases

OBJECTIVE: To study the putative effects of Advanced Oxidation Protein Products (AOPPs) and Advanced Glycation End Products (AGEs) in the development and progression of cardiovascular disease (CVD). METHODOLOGY: AGEs, AOPPs, e-NOS, lipid profile, circulating stress and inflammatory biomarkers were e...

Descripción completa

Detalles Bibliográficos
Autores principales: Rasool, Mahmood, Malik, Arif, Butt, Tariq Tahir, Ashraf, Muhammad Abdul Basit, Rasool, Rabia, Zahid, Ayesha, Waquar, Sulayman, Asif, Muhammad, Zaheer, Ahmad, Jabbar, Abdul, Zain, Maryam, Mehmood, Asim, Qaisrani, Tahira Batool, Malik, Imran Riaz, Khan, Sami Ullah, Mirza, Zeenat, Haque, Absarul, Al-Qahtani, Mohammed Hussein, Karim, Sajjad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717110/
https://www.ncbi.nlm.nih.gov/pubmed/31485173
http://dx.doi.org/10.1016/j.sjbs.2018.08.024
_version_ 1783447497942761472
author Rasool, Mahmood
Malik, Arif
Butt, Tariq Tahir
Ashraf, Muhammad Abdul Basit
Rasool, Rabia
Zahid, Ayesha
Waquar, Sulayman
Asif, Muhammad
Zaheer, Ahmad
Jabbar, Abdul
Zain, Maryam
Mehmood, Asim
Qaisrani, Tahira Batool
Malik, Imran Riaz
Khan, Sami Ullah
Mirza, Zeenat
Haque, Absarul
Al-Qahtani, Mohammed Hussein
Karim, Sajjad
author_facet Rasool, Mahmood
Malik, Arif
Butt, Tariq Tahir
Ashraf, Muhammad Abdul Basit
Rasool, Rabia
Zahid, Ayesha
Waquar, Sulayman
Asif, Muhammad
Zaheer, Ahmad
Jabbar, Abdul
Zain, Maryam
Mehmood, Asim
Qaisrani, Tahira Batool
Malik, Imran Riaz
Khan, Sami Ullah
Mirza, Zeenat
Haque, Absarul
Al-Qahtani, Mohammed Hussein
Karim, Sajjad
author_sort Rasool, Mahmood
collection PubMed
description OBJECTIVE: To study the putative effects of Advanced Oxidation Protein Products (AOPPs) and Advanced Glycation End Products (AGEs) in the development and progression of cardiovascular disease (CVD). METHODOLOGY: AGEs, AOPPs, e-NOS, lipid profile, circulating stress and inflammatory biomarkers were evaluated among fifty cardiovascular patients and fifty controls. Independent student’s t-test was done for statistical analysis. RESULTS: The malondialdehyde mean level in CVD patients (5.45 nmol/ml) was significantly higher than control (1.36 nmol/ml) (p value = 0.018). Nitric oxide in CVD patients (55.72 ng/ml) was remarkably increased as compared to normal subjects (19.19 ng/ml). A significant change in the mean serum level of AGEs in CVD patients (2.74 ng/ml) and normal individuals (0.85 ng/ml) was recorded (p value = 0.000). The AOPPs also showed significant increased levels in CVD group (132.07 ng/ml) in comparison with normal subjects (83.05 ng/ml) (p value = 0.011). The mean eNOS serum level in CVD group (15.50 U/L) was higher than control group (11.28 U/L) (p value = 0.004). Cardiovascular disease patients, in comparison with healthy controls, showed increased level of total cholesterol (5.48 mmol/L vs 4.45 mmol/L), triglycerides (2.59 mmol/L vs 1.24 mmol/L), and low density lipoprotein (2.47 mmol/L vs 2.31 mmol/L) along with decrease in high density lipoprotein (1.39 mmol/L vs 1.74 mmol/L). The mean MMP-11 serum levels in CVD group (98.69 ng/ml) was almost double of control group (45.60 ng/ml) (p value = 0.017). The mean serum level of TNF-α and IL1-α were 32.16 pg/ml and 6.64 pg/ml in CVD patient. The significant decreasing trend of SOD (p value = 0.041), CAT (p value = 0.018), GSH (p value = 0.036) and GRx (p value = 0.029) but increasing drift of GPx (0.023) level was observed in CVD patients. CONCLUSION: This study provides strong evidence that CVD patients presented with elevated oxidative stress, enhanced inflammation and lipid profile in their serum. Therefore, the study strongly approves that AGEs, AOPPs, inflammatory and lipoxidative biomarkers hold predictive potential in causing and aggravating the disease, thus by controlling these factors CVD progression can be inhibited.
format Online
Article
Text
id pubmed-6717110
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-67171102019-09-04 Implications of advanced oxidation protein products (AOPPs), advanced glycation end products (AGEs) and other biomarkers in the development of cardiovascular diseases Rasool, Mahmood Malik, Arif Butt, Tariq Tahir Ashraf, Muhammad Abdul Basit Rasool, Rabia Zahid, Ayesha Waquar, Sulayman Asif, Muhammad Zaheer, Ahmad Jabbar, Abdul Zain, Maryam Mehmood, Asim Qaisrani, Tahira Batool Malik, Imran Riaz Khan, Sami Ullah Mirza, Zeenat Haque, Absarul Al-Qahtani, Mohammed Hussein Karim, Sajjad Saudi J Biol Sci Article OBJECTIVE: To study the putative effects of Advanced Oxidation Protein Products (AOPPs) and Advanced Glycation End Products (AGEs) in the development and progression of cardiovascular disease (CVD). METHODOLOGY: AGEs, AOPPs, e-NOS, lipid profile, circulating stress and inflammatory biomarkers were evaluated among fifty cardiovascular patients and fifty controls. Independent student’s t-test was done for statistical analysis. RESULTS: The malondialdehyde mean level in CVD patients (5.45 nmol/ml) was significantly higher than control (1.36 nmol/ml) (p value = 0.018). Nitric oxide in CVD patients (55.72 ng/ml) was remarkably increased as compared to normal subjects (19.19 ng/ml). A significant change in the mean serum level of AGEs in CVD patients (2.74 ng/ml) and normal individuals (0.85 ng/ml) was recorded (p value = 0.000). The AOPPs also showed significant increased levels in CVD group (132.07 ng/ml) in comparison with normal subjects (83.05 ng/ml) (p value = 0.011). The mean eNOS serum level in CVD group (15.50 U/L) was higher than control group (11.28 U/L) (p value = 0.004). Cardiovascular disease patients, in comparison with healthy controls, showed increased level of total cholesterol (5.48 mmol/L vs 4.45 mmol/L), triglycerides (2.59 mmol/L vs 1.24 mmol/L), and low density lipoprotein (2.47 mmol/L vs 2.31 mmol/L) along with decrease in high density lipoprotein (1.39 mmol/L vs 1.74 mmol/L). The mean MMP-11 serum levels in CVD group (98.69 ng/ml) was almost double of control group (45.60 ng/ml) (p value = 0.017). The mean serum level of TNF-α and IL1-α were 32.16 pg/ml and 6.64 pg/ml in CVD patient. The significant decreasing trend of SOD (p value = 0.041), CAT (p value = 0.018), GSH (p value = 0.036) and GRx (p value = 0.029) but increasing drift of GPx (0.023) level was observed in CVD patients. CONCLUSION: This study provides strong evidence that CVD patients presented with elevated oxidative stress, enhanced inflammation and lipid profile in their serum. Therefore, the study strongly approves that AGEs, AOPPs, inflammatory and lipoxidative biomarkers hold predictive potential in causing and aggravating the disease, thus by controlling these factors CVD progression can be inhibited. Elsevier 2019-02 2018-08-27 /pmc/articles/PMC6717110/ /pubmed/31485173 http://dx.doi.org/10.1016/j.sjbs.2018.08.024 Text en © 2018 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Rasool, Mahmood
Malik, Arif
Butt, Tariq Tahir
Ashraf, Muhammad Abdul Basit
Rasool, Rabia
Zahid, Ayesha
Waquar, Sulayman
Asif, Muhammad
Zaheer, Ahmad
Jabbar, Abdul
Zain, Maryam
Mehmood, Asim
Qaisrani, Tahira Batool
Malik, Imran Riaz
Khan, Sami Ullah
Mirza, Zeenat
Haque, Absarul
Al-Qahtani, Mohammed Hussein
Karim, Sajjad
Implications of advanced oxidation protein products (AOPPs), advanced glycation end products (AGEs) and other biomarkers in the development of cardiovascular diseases
title Implications of advanced oxidation protein products (AOPPs), advanced glycation end products (AGEs) and other biomarkers in the development of cardiovascular diseases
title_full Implications of advanced oxidation protein products (AOPPs), advanced glycation end products (AGEs) and other biomarkers in the development of cardiovascular diseases
title_fullStr Implications of advanced oxidation protein products (AOPPs), advanced glycation end products (AGEs) and other biomarkers in the development of cardiovascular diseases
title_full_unstemmed Implications of advanced oxidation protein products (AOPPs), advanced glycation end products (AGEs) and other biomarkers in the development of cardiovascular diseases
title_short Implications of advanced oxidation protein products (AOPPs), advanced glycation end products (AGEs) and other biomarkers in the development of cardiovascular diseases
title_sort implications of advanced oxidation protein products (aopps), advanced glycation end products (ages) and other biomarkers in the development of cardiovascular diseases
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717110/
https://www.ncbi.nlm.nih.gov/pubmed/31485173
http://dx.doi.org/10.1016/j.sjbs.2018.08.024
work_keys_str_mv AT rasoolmahmood implicationsofadvancedoxidationproteinproductsaoppsadvancedglycationendproductsagesandotherbiomarkersinthedevelopmentofcardiovasculardiseases
AT malikarif implicationsofadvancedoxidationproteinproductsaoppsadvancedglycationendproductsagesandotherbiomarkersinthedevelopmentofcardiovasculardiseases
AT butttariqtahir implicationsofadvancedoxidationproteinproductsaoppsadvancedglycationendproductsagesandotherbiomarkersinthedevelopmentofcardiovasculardiseases
AT ashrafmuhammadabdulbasit implicationsofadvancedoxidationproteinproductsaoppsadvancedglycationendproductsagesandotherbiomarkersinthedevelopmentofcardiovasculardiseases
AT rasoolrabia implicationsofadvancedoxidationproteinproductsaoppsadvancedglycationendproductsagesandotherbiomarkersinthedevelopmentofcardiovasculardiseases
AT zahidayesha implicationsofadvancedoxidationproteinproductsaoppsadvancedglycationendproductsagesandotherbiomarkersinthedevelopmentofcardiovasculardiseases
AT waquarsulayman implicationsofadvancedoxidationproteinproductsaoppsadvancedglycationendproductsagesandotherbiomarkersinthedevelopmentofcardiovasculardiseases
AT asifmuhammad implicationsofadvancedoxidationproteinproductsaoppsadvancedglycationendproductsagesandotherbiomarkersinthedevelopmentofcardiovasculardiseases
AT zaheerahmad implicationsofadvancedoxidationproteinproductsaoppsadvancedglycationendproductsagesandotherbiomarkersinthedevelopmentofcardiovasculardiseases
AT jabbarabdul implicationsofadvancedoxidationproteinproductsaoppsadvancedglycationendproductsagesandotherbiomarkersinthedevelopmentofcardiovasculardiseases
AT zainmaryam implicationsofadvancedoxidationproteinproductsaoppsadvancedglycationendproductsagesandotherbiomarkersinthedevelopmentofcardiovasculardiseases
AT mehmoodasim implicationsofadvancedoxidationproteinproductsaoppsadvancedglycationendproductsagesandotherbiomarkersinthedevelopmentofcardiovasculardiseases
AT qaisranitahirabatool implicationsofadvancedoxidationproteinproductsaoppsadvancedglycationendproductsagesandotherbiomarkersinthedevelopmentofcardiovasculardiseases
AT malikimranriaz implicationsofadvancedoxidationproteinproductsaoppsadvancedglycationendproductsagesandotherbiomarkersinthedevelopmentofcardiovasculardiseases
AT khansamiullah implicationsofadvancedoxidationproteinproductsaoppsadvancedglycationendproductsagesandotherbiomarkersinthedevelopmentofcardiovasculardiseases
AT mirzazeenat implicationsofadvancedoxidationproteinproductsaoppsadvancedglycationendproductsagesandotherbiomarkersinthedevelopmentofcardiovasculardiseases
AT haqueabsarul implicationsofadvancedoxidationproteinproductsaoppsadvancedglycationendproductsagesandotherbiomarkersinthedevelopmentofcardiovasculardiseases
AT alqahtanimohammedhussein implicationsofadvancedoxidationproteinproductsaoppsadvancedglycationendproductsagesandotherbiomarkersinthedevelopmentofcardiovasculardiseases
AT karimsajjad implicationsofadvancedoxidationproteinproductsaoppsadvancedglycationendproductsagesandotherbiomarkersinthedevelopmentofcardiovasculardiseases